A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
← catalyst calendarNCT07301034 · readout in 818 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
332estimated
Sites
20
Countries
Austria, Denmark, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-18 | actual | When the study began enrolling |
| Primary completion | 2028-11-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-24 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myocardial Infarction
Interventions
- Drug: Ziltivekimab
- Drug: Ziltivekimab Placebo
Primary outcome
what the primary-completion date above is the date OFChange in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interest
measured From randomisation (week 0) to end-of-study (52-week)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed